Tuesday, July 1, 2025 7/1/2025

Personalized Organoid-Chip Model For Drug Testing in Pancreatic Cancer

Award Number: R21CA277110
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 02/01/2023
PERIOD OF PERFORMANCE END DATE: 01/31/2026

Group Awards By:

View Award Description

Personalized Organoid-Chip Model For Drug Testing in Pancreatic Cancer - ABSTRACT In order to improve cancer patient outcomes, the next generation of cancer therapeutics should combine targeted treatments with the ability to predict the likelihood of an individual’s tumor to benefit from a given treatment. The focus of this project is on advancing a personalized platform based on the individual’s tumor behavior which is determined not only by the cancerous epithelium but the entire tumor microenvironment (TME). The role of TME in disease progression or even therapeutic drug response is well established in variety of cancers with poor outcome including pancreatic ductal adenocarcinoma (PDA) with a five year survival rate of less than 10%. Here, combining 3D patient-derived organoids (PDO) and microfluidic technologies, we will develop a novel tumor-chip device with the potential to generate individualized treatment response predictions ex vivo. In Aim 1, using multiple tissue and functional read outs we will show that our multicellular platform recapitulates the tumor and its microenvironment. In Aim 2, we will show the utility of our system as an individualized ex vivo platform to functionally characterize the tumor response to conventional and novel therapies. Our long-term goal is to optimize patient-specific ex vivo drug response assay technology such that it may be used to rapidly, accurately, and reliably inform individualized treatment decisions. As a proof of concept, the project involves developing a personalized pancreatic cancer model; however this technology can be extended to other solid tumor types with rich TME (i.e., breast cancer) to improve molecular and/or cellular characterizations of cancer biology and therapeutics.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2024	RUSH UNIVERSITY MEDICAL CENTER	1653 W CONGRESS PKWY	CHICAGO	IL	60612	COOK	USA	Cancer Treatment Research	000	2	2/27/2025	NON-COMPETING CONTINUATION	-$34,997
2025	2024	UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON	7000 FANNIN ST FL 9	HOUSTON	TX	77030	HARRIS	USA	Cancer Treatment Research	001	3	2/27/2025	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$34,997
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $180,780 )
2024	2024	RUSH UNIVERSITY MEDICAL CENTER	1653 W CONGRESS PKWY	CHICAGO	IL	60612	COOK	USA	Cancer Treatment Research	001	2	4/25/2024	NON-COMPETING CONTINUATION	$9,514
2024	2024	RUSH UNIVERSITY MEDICAL CENTER	1653 W CONGRESS PKWY	CHICAGO	IL	60612	COOK	USA	Cancer Treatment Research	000	2	1/25/2024	NON-COMPETING CONTINUATION	$171,266
2024	2024	RUSH UNIVERSITY MEDICAL CENTER	1653 W CONGRESS PKWY	CHICAGO	IL	60612	COOK	USA	Cancer Treatment Research	002	2	7/23/2024	NON-COMPETING CONTINUATION	-$120,139
2024	2024	UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON	7000 FANNIN ST FL 9	HOUSTON	TX	77030	HARRIS	USA	Cancer Treatment Research	003	3	7/23/2024	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$120,139
														Subtotal = $180,780

Issue Date FY: 2023 ( Subtotal = $228,839 )
2023	2023	RUSH UNIVERSITY MEDICAL CENTER	1620 W HARRISON ST	CHICAGO	IL	60612	COOK	USA	Cancer Treatment Research	000	1	1/11/2023	NEW	$228,839
														Subtotal = $228,839

Grand Total All Awards = $409,619

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Personalized Organoid-Chip Model For Drug Testing in Pancreatic Cancer

Award Number: R21CA277110

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 02/01/2023

PERIOD OF PERFORMANCE END DATE: 01/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer